Article 449: JAMA Editorial Policy Questioned

• Academics and industry observers say a new JAMA policy, while attempting to address important issues of publication bias and misleading reporting of data, unfairly single out industry-sponsored studies. The British Medical Journal (BMJ) called the new policy unfair and absurd. Organizations such as the Association of Clinical Research Organizations, the Pharmaceutical Research and Manufacturers of America, the International Society for Pharmacoepidemiology and the Royal Statistical Society, have urged JAMA to reconsider its policy.

Article 450: eDiary Pros—and a Few Cons

• When the FDA releases its much anticipated guidance on patient reported outcomes, which will apply both to paper and electronic diaries, eDiary vendors expect it will drive a more rapid transition from paper to electronic diaries; some predict that anywhere from 25% to 40% percent of patient diaries used in clinical trials will be electronic next year. Contract research organizations are increasingly working with eDiary vendors—another signal that pharmaceutical companies are comfortable with the handful of eDiary companies.

Article 451: Turkey's Emerging Clinical Research Market

• Turkey is beginning to emerge as a global market for the clinical trials industry.

Article 452: Eye on: Brain Cancer

• Annual incidence of primary brain cancer in the U.S. is about 17,000 cases CenterWatch has identified a pipeline of 16 drugs in development for brain cancer.